Regeneron announced that the Eylea (aflibercept) prefilled syringe is now available for doctors to order.
The 2 mg, single-dose, sterilized prefilled syringe provides physicians with a new way to administer Eylea that requires fewer preparation steps compared to vials.
Eylea is the only anti-VEGF approved to treat four retinal conditions with a single dose strength prefilled syringe. In the United States, Eylea is indicated to treat wet age-related macular degeneration (AMD) with dosing options every 4 or 8 weeks following an initial monthly dosing period or 12 weeks after one year of effective therapy, and for all stages of diabetic retinopathy (DR) and diabetic macular edema (DME) every 4 or 8 weeks, following an initial dosing period.
In August, Regeneron received FDA approval for the Eylea prefilled syringe, which the company says requires fewer preparation steps compared to vials. The sterilized prefilled syringe offers the same medicine as the currently available Eylea.